Search

everythinglearnresearchcommunity

for

Search:↓

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Finasteride effectively treats baldness but may cause sexual side effects.

Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Testosterone increases muscle mass regardless of DHT conversion blocking.

Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.

Finasteride treats hair loss but may cause side effects like low libido and dizziness.

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.

Finasteride and dutasteride are equally effective and safe for treating BPH.

Finasteride effectively treats BPH, but needs more trials to understand potential.

Finasteride didn't significantly improve ICPPS symptoms, more research needed.

Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.

Dutasteride reduces DHT more effectively than finasteride.

Large prostate links to more hair loss, but age of onset doesn't affect it.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Male pattern baldness may predict prostate cancer risk.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.